BIIB Jan 2025 280.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:03PM EDT. Market open.
| Previous close | 47.40 |
| Open | 47.40 |
| Bid | 50.30 |
| Ask | 56.20 |
| Strike | 280.00 |
| Expiry date | 2025-01-17 |
| Day's range | 47.40 - 47.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 56 |
GuruFocus.comDecoding Biogen Inc (BIIB): A Strategic SWOT Insight
Insightful Analysis of Biogen Inc's Financials and Strategic Positioning
GlobeNewswireBiogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFID
ZacksBiotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
© 2024 Yahoo. All rights reserved.